- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05804045
Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)
A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study of ABSK021 to Assess the Efficacy and Safety in Patients With Tenosynovial Giant Cell Tumor
The goal of this clinical trial is to assess the efficacy and safety of Pimicotinib (ABSK021) in patients with Tenosynovial Giant Cell Tumor (TGCT). The main questions it aims to answer are:
- Whether the Pimicotinib(ABSK021) works well in patients with TGCT.
- Whether the Pimicotinib(ABSK021) is safe in patients with TGCT.
Participants will be asked to complete the study procedures:
- Receive the administration of Pimicotinib(ABSK021) or placebo (a placebo is a look-alike substance that contains no active drug) about 24 weeks in study part 1.
- Receive the administration of Pimicotinib(ABSK021) about 24 weeks in study part 2.
- Receive the administration of Pimicotinib(ABSK021) till study end in study part 3.
- Complete the study procedures speficied in the protocol, which is guided by researchers.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study consists of part 1 and part 2. Part 1 is a double-blind phase, eligible patients will be randomized to Pimicotinib(ABSK021) treatment group or matching placebo group and will receive Pimicotinib(ABSK021) or matching placebo until completion of Part 1.
Part 2 is an open-label treatment phase, and all patients entering this phase will receive open-label Pimicotinib(ABSK021) until completion of 24 weeks of dosing or withdrawal from the study.
Part 3 is an open-label extension treatment phase, and patients who completed the part 2 and continuted to be eligible, will go to the Part 3. Patients will receive the open-label Pimicotinib(ABSK021) until all patients withdraw from the study, or the sponsor decides to terminate the study, whichever occurs first.
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: YUAN LU
- Phone Number: +86-21-68910052
- Email: clinical@abbisko.cn
Study Locations
-
-
-
Montréal, Canada
- McGill University Health center
-
Toronto, Canada
- Princess Margaret Cancer Center
-
-
-
-
-
Beijing, China
- BeiJing JiShuiTan Hospital
-
-
Anhui
-
Bengbu, Anhui, China
- The First Affiliated Hospital of Bengbu Medical College
-
-
Beijing
-
Beijing, Beijing, China
- Peking University People's Hospital
-
-
Fujian
-
Fuzhou, Fujian, China
- The First Affiliated Hospital Of Fujian Medical University
-
-
Guangdong
-
Guangzhou, Guangdong, China
- The First Affiliated Hospital, Sun Yat-sen University
-
Guangzhou, Guangdong, China
- Guangdong Provincial People's Hospital
-
Guangzhou, Guangdong, China
- The First Affiliated Hospital of Jinan University
-
-
Guizhou
-
Guiyang, Guizhou, China
- The Affiliated Hospital of Guizhou Medical University
-
-
Henan
-
Zhengzhou, Henan, China
- Henan Cancer Hospital
-
-
Hubei
-
Enshi, Hubei, China
- The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture
-
Wuhan, Hubei, China
- Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology
-
-
Hunan
-
Changsha, Hunan, China
- The Second Xiangya Hospital Of Central South University
-
Changsha, Hunan, China
- Hunan Provincial People's Hospital
-
-
Jiangsu
-
Nanjing, Jiangsu, China
- Nanjing Drum Tower hospital
-
-
Liaoning
-
Shenyang, Liaoning, China
- Liaoning Cancer Hospital&Institute
-
-
Shandong
-
Weifang, Shandong, China
- Weifang people's Hospital
-
-
Shanghai
-
Shanghai, Shanghai, China
- Shanghai General Hospital
-
-
Shanxi
-
Taiyuan, Shanxi, China
- The Second Hospital of Shanxi Medical University
-
Xi'an, Shanxi, China
- Xi'an Honghui Hospital
-
-
Wuhan
-
Chengdu, Wuhan, China
- West China Hospital Sichuan University
-
-
Xinjiang
-
Ürümqi, Xinjiang, China
- The first affiliated hospital of Xinjiang medical university
-
-
Zhejiang
-
Hangzhou, Zhejiang, China
- Zhejiang Cancer Hospital
-
Hangzhou, Zhejiang, China
- The Second Affiliated Hospital Zhejiang University School of Medicine
-
-
-
-
-
Bologna, Italy
- IRCCS Istituto Ortopedico Rizzoli
-
Milano, Italy
- Fondazione IRCCS Istituto Nazionale dei Tumori
-
Prato, Italy
- Ospedale di Prato
-
-
-
-
-
Leiden, Netherlands, 2333
- Leiden University Medical Center
-
-
-
-
-
Warsaw, Poland
- Maria Sklodowska-Curie National Research Institute of Oncology
-
-
-
-
-
Barcelona, Spain
- Hospital Universitari Vall d'Hebron
-
Madrid, Spain, 28040
- Fundacion Jimenez Diaz
-
-
-
-
California
-
Beverly Hills, California, United States, 90212
- Precision NextGen Oncology
-
-
Michigan
-
Detroit, Michigan, United States, 48202
- Henry Ford Health System
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- The Cleveland Clinic Foundation
-
Columbus, Ohio, United States, 43210
- The Ohio State University
-
-
Texas
-
Houston, Texas, United States, 77030
- The University of Texas M.D. Anderson Cancer Center
-
-
Washington
-
Seattle, Washington, United States, 98109
- Fred Hutchinson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients should understand the study procedures and sign the informed consent form prior to screening.
- Age ≥ 18 years.
- A histologically confirmed TGCT with unresectable.
- Measurable disease as defined by RECIST 1.1, and with at least one lesion of ≥ 2 cm.
- Stable prescription of analgesic regimen for patients with an analgesic need.
- Participants should complete stiffness and pain scales during the screening period, and symptomatic disease because of active TGCT should meet minimum requirements as outlined in study protocol.
- ECOG PS (Eastern Cooperative Oncology Group Performance Status) of 0 or 1.
- Adequate organ function and bone marrow function.
Exclusion Criteria:
- Known allergy or hypersensitivity to any components of the investigational drug product.
- Previous treatment with highly selective inhibitors targeting CSF-1/CSF-1R. Previous therapy with imatinib and nilotinib is allowed.
- Known additional malignancy that required active treatment and may affect the patient's participation in the study or affect the outcome of the study as assessed by the Investigator.
- Known metastatic TGCT.
- Significant concomitant arthropathy in the affected joint, serious disease, uncontrolled infection.
- Known MRI contraindications.
- Has factors that significantly affected the absorption of oral drug.
- Major surgery or previous anti-tumor therapy for TGCT within 4 weeks prior to randomization.
- Concomitant use of strong CYP inhibitors or inducers as outlined in study protocol.
- Impaired cardiac function or clinically significant cardiac disease.
- Known active human immunodeficiency virus, active hepatitis B, active hepatitis C, or known active tuberculosis.
- Known active liver or biliary disease, or other diseases that may lead to abnormal liver function test results during the study.
- Pregnant or lactating women.
- Childbearing potential males or non-surgically sterilized female patients must agree to use effective methods of contraception during the study.
- Any other clinically significant comorbidities, which in the judgment of the Investigator, could compromise compliance with the protocol, interfere with the interpretation of study results, or predispose the patient to safety risks.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Part 1/Part 2/Part 3- Pimicotinib(ABSK021)/ Pimicotinib(ABSK021)
Participants receive the blinded treatment of ABSK021 for 24 weeks in Part 1 and continue on the open-label Pimicotinib(ABSK021) in Part 2 and Part 3.
|
capsule
|
Placebo Comparator: Part 1- Placebo/ Pimicotinib(ABSK021)
Participants receive the blinded treatment of matching placebo for 24 weeks in Part 1 and have option to receive the open-label Pimicotinib(ABSK021) in Part 2.
|
capsule
capsule
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate (ORR)
Time Frame: Baseline to Week 25
|
Assessed by central read using Response Evaluation Criteria in Solid Tumors (RECIST) (Version 1.1)
|
Baseline to Week 25
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate (ORR) per Tumor Volume Score (TVS)
Time Frame: Baseline to Week 25
|
Assessed by central read using Tumor Volume Score (TVS).
TVS is a semi-quantitative MRI scoring system that describes tumor mass and is based on 10% increments of the estimated volume of the maximally distended synovial cavity or tendon sheath involved.
A tumor that is equal in volume to that of a maximally distended synovial cavity or tendon sheath was scored 10; a score of 0 indicated no evidence of tumor.
|
Baseline to Week 25
|
Range of Motion (ROM)
Time Frame: Baseline to Week 25
|
Mean change from baseline in ROM of the affected joint
|
Baseline to Week 25
|
Worst Stiffness
Time Frame: Baseline to Week 25
|
Mean change from baseline in the Worst Stiffness Numeric Rating Scale (NRS) score at Week 25.
The Worst Stiffness Numeric Rating Scale (NRS) was a 1-item, self-administered questionnaire assessing the "worst" stiffness in the last 24 hours.
The NRS for this item ranged from 0 (no stiffness) to 10 (stiffness as bad as you can imagine).
Higher scores mean a worse outcomes.
|
Baseline to Week 25
|
Worst Pain
Time Frame: Baseline to Week 25
|
Mean change from baseline in the Worst Pain Numeric Rating Scale (NRS) score at Week 25.
The Worst Pain Numeric Rating Scale Score (NRS) was a 1-item, self-administered questionnaire assessing the "worst" pain in the last 24 hours.
The NRS for this item ranged from 0 (no pain) to 10 (pain as bad as you can imagine).
Higher scores mean a worse outcomes.
|
Baseline to Week 25
|
Physical Function
Time Frame: Baseline to Week 25
|
Mean change from baseline in the Patient-reported Outcomes Measurement Information System (PROMIS) Physical Function score at Week 25.
The Patient-reported Outcomes Measurement Information System (PROMIS) physical function scale was used to assess physical function of the upper and lower limbs.
The scale ranged from 1 defined as 'unable to do' or 'cannot do' to 5 defined as 'without any difficulty' or 'not at all', where higher scores represent better outcomes.
|
Baseline to Week 25
|
Quality of life (QoL)
Time Frame: Baseline to Week 25
|
Mean change from baseline in EuroQol visual analogue scale (VAS) score at Week 25.
The EuroQol visual analogue scale (VAS) is a Visual Analogue Scale on which the patient rates their current health, with 0 representing the "worst health you can imagine" and 100 representing the "best health you can imagine".
Higher scores mean a better outcomes.
|
Baseline to Week 25
|
Duration of Response (DOR)
Time Frame: The time (months) from the first documentation of objective response to the first documentation of radiographic disease progression (PD) or death due to any cause, whichever occurs first, assessed up to 24 months.
|
Duration of Response as measured by RECIST Version 1.1 and Tumor Volume Score (TVS)
|
The time (months) from the first documentation of objective response to the first documentation of radiographic disease progression (PD) or death due to any cause, whichever occurs first, assessed up to 24 months.
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ABSK021-301
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tenosynovial Giant Cell Tumor
-
Deciphera Pharmaceuticals LLCActive, not recruitingTenosynovial Giant Cell Tumor | Giant Cell Tumor of Tendon Sheath | Pigmented Villonodular Synovitis | Tenosynovial Giant Cell Tumor, Diffuse | Tenosynovial Giant Cell Tumor, LocalizedNorway, United States, France, Spain, Hong Kong, Netherlands, Italy, Germany, Australia, United Kingdom, Canada, Poland, Switzerland
-
Deciphera Pharmaceuticals LLCActive, not recruitingAdvanced Malignant Neoplasm | Tenosynovial Giant Cell Tumor | Giant Cell Tumor of Tendon Sheath | Pigmented Villonodular Synovitis | Tenosynovial Giant Cell Tumor, DiffuseUnited States, France, Spain, United Kingdom, Netherlands, Canada, Italy, Australia, Poland
-
Novartis PharmaceuticalsCompletedPigmented Villonodular Synovitis | PVNS | Giant Cell Tumor of the Tendon Sheath | GCCTS | Tenosynovial Giant Cell Tumor Localized or Diffused Type | GCTSUnited States, Switzerland
-
Daiichi Sankyo Co., Ltd.Active, not recruitingTenosynovial Giant Cell TumorTaiwan, China
-
Andrew J. Wagner, MD, PhDMassachusetts General Hospital; Novartis; Brigham and Women's HospitalActive, not recruitingTenosynovial Giant Cell Tumor | Pigmented Villonodular Synovitis | Diffuse-type Giant Cell TumorUnited States
-
Daiichi Sankyo, Inc.CompletedTenosynovial Giant Cell TumorUnited States, Spain, Taiwan, Australia, Hungary, Italy, Netherlands
-
SynOx Therapeutics LimitedNot yet recruiting
-
Daiichi Sankyo Co., Ltd.RecruitingTenosynovial Giant Cell TumorJapan
-
Daiichi Sankyo, Inc.RecruitingTenosynovial Giant Cell Tumor | HepatotoxicityUnited States
-
Abbisko Therapeutics Co, LtdRecruitingNeoplasms | Tenosynovial Giant Cell TumorUnited States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States